Front-Runner in Next-Gen Immuno-Oncology Treatments
Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs in oncology, autoimmune, and other severe diseases both in China and globally, with a particular focus on diseases that remain untreated by existing therapies, represented by PD-1/PD-L1.
14
INNOVATIVE DRUG CANDIDATES
6
CLINICAL-STAGE DRUG CANDIDATES
4
TOP-TIER CLINICALLY ADVANCED CANDIDATES
Systematic Deployment Targeting Multiple Immune Pathways
- Novel combination therapies featuring multiple targets, diverse molecular platform, and varied technological approaches will represent the future of cancer immunotherapy
- Leads Biolabs has strategically developed assets in all three areas, exploring multi approach combination therapies to provide extensive cancer treatment options
Integrated In-House Capabilities Encompassing R&D, Clinical Development, CMC and Business Development
We successfully established a comprehensive R&D platform for antibody discovery and engineering, in vivo and in vitro efficacy evaluation, druggability assessment, achieving an efficient drug development process
3years from target selection to investigational new drug (IND) submission
*outpacing the industry average of approximately five to six years, according to Frost & Sullivan
Global Collaborations
Leverage the global competitiveness and differentiated strengths of our pipeline to establish global collaborations through diverse approaches, accelerating global commercialization to benefit patients worldwide
Out-Licensing
Establish strategic partnerships and grant exclusive licenses for rights outside Greater China
NewCo
Establish a joint venture with venture capital firms to consolidate resources, technologies, and expertise, propelling the advancement of drug development and innovation
Collaborative Development
Establish co-development partnerships to share resources and technologies, accelerating the development and commercialization of revolutionary therapies
Press Releases
'%20fill='%23868686'%20fill-rule='nonzero'%3e%3cg%20id='icon_qx'%20transform='translate(343,%20613)'%3e%3cpath%20d='M14.7073469,13.2954501%20L8.91225312,7.50026721%20L14.7073246,1.70450489%20C14.8962609,1.51559088%2015.0001781,1.26441124%2015,0.997208354%20C14.9998215,0.730807741%2014.8960603,0.480742374%2014.7078594,0.293076342%20C14.5193688,0.104095468%2014.2690361,0.000155995232%2014.0025909,0%20C13.7350091,0%2013.4840969,0.103917194%2013.2953612,0.292586056%20L7.50042344,6.0875461%20L1.70450512,0.292586078%20C1.51583626,0.103917216%201.26512461,0%200.998545704,0%20C0.731989095,0%200.481277447,0.103894915%200.292630864,0.292541498%20C0.104028861,0.480630937%200.000178524818,0.730807741%200,0.997208354%20C-0.000178045047,1.26441124%200.103739127,1.51559088%200.292630864,1.70448261%20L6.0885046,7.50024494%20L0.292608586,13.2954724%20C0.103917423,13.4841413%200,13.7348083%200,14.0014095%20C0,14.2679661%200.103939724,14.5187%200.292630886,14.7073912%20C0.481277469,14.8960601%200.731966816,14.9999327%200.998523446,14.9999327%20C1.26510236,14.9999327%201.51583628,14.8960378%201.70448287,14.7073912%20L7.50033432,8.91227517%20L13.2954726,14.7073912%20C13.4841415,14.8960601%2013.735076,14.9999327%2014.0020115,14.9999327%20C14.2691252,14.9997544%2014.5192129,14.8960155%2014.7069458,14.7078369%20C15.0964959,14.3182422%2015.0966073,13.6847106%2014.7073469,13.2954501%20Z'%20id='路径'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)